SCM
ITOS

Silverarc Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Silverarc Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-138,843
Closed -$4.47M – 78
2022
Q1 		$4.47M Buy
138,843
+837
+0.6% +$30.4K 1.85% 13
2021
Q4 		$6.43M Buy
138,006
+21,075
+18% +$702K 2.6% 13
2021
Q3 		$3.16M Buy
116,931
+41,420
+55% +$1.08M 1.78% 19
2021
Q2 		$1.94M Buy
+75,511
New +$1.8M 0.86% 43

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Silverarc Capital Management's ITOS Position: Q2 2022 in Review

Silverarc Capital Management sold out of iTeos Therapeutics (ITOS) in Q2 2022, closing a stake of 138,843 shares — an estimated $4.47M sold.

Silverarc Capital Management first reported a position in ITOS in Q2 2021 and held it in 4 quarters. The position peaked at $6.43M in Q4 2021. 152 funds tracked by Wall St. Rank hold ITOS as of Q2 2022.

  • Silverarc Capital Management reported no remaining iTeos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Silverarc Capital Management sold 138,843 iTeos Therapeutics shares in Q2 2022, an estimated $4.47M.
  • Silverarc Capital Management first reported a position in iTeos Therapeutics in Q2 2021 and held it in 4 quarters.
  • Silverarc Capital Management's iTeos Therapeutics position peaked at $6.43M in Q4 2021.
  • 152 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2022.

Based on Silverarc Capital Management's 13F filing for Q2 2022, filed 25 Jul 2022.